XML 51 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Research and Development Activity (Details) - USD ($)
1 Months Ended 12 Months Ended
Jun. 10, 2021
Jul. 31, 2021
Mar. 31, 2019
Dec. 31, 2021
Dec. 31, 2020
Research and Development Activity (Details) [Line Items]          
Common stock issued (in Shares) 192,533     17,843,303 13,481,283
Common stock equal to fully diluted shares to purchase with fair value 10.00%        
Cash payment $ 15,000,000        
Stock issued $ 3,300,000        
Annual maintenance fees, description       Annual maintenance fees under the PITT Agreement include: $5,000 due June 26 of each year 2020-2022; $10,000 due on June 26 of each year 2023-2024; and $25,000 due on June 26 of each year 2025 and annually thereafter until first commercial sale. The Company had no amounts owed pursuant to the PITT Agreement as of December 31, 2021.   
Milestone payment     $ 50,000    
Xencor, Inc. License Agreement [Member]          
Research and Development Activity (Details) [Line Items]          
Non refundable fee       $ 100,000  
Common stock issued (in Shares)       1,585,000  
Common stock with fair value on discounted cash flow       $ 12,221,000  
Fair value of warrants       $ 4,193,000  
Common stock equal to fully diluted shares to purchase with fair value       10.00%  
Aggregate purchase price for exercise of option pro-rated for any partial exercise       $ 10,000,000  
Intangible assets       $ 16,514,000  
Immune Ventures [Member]          
Research and Development Activity (Details) [Line Items]          
Milestone payment   $ 25,000      
Agreement expiry period, description       The PITT Agreement expires upon the earlier of: (i) expiration of the last claim of the Patent Rights forming the subject matter of the PITT Agreement; or (ii) the date that is 20 years from the effective date of the agreement (June 26, 2037).  
Immune Ventures [Member]          
Research and Development Activity (Details) [Line Items]          
Percentage of licensor royalty patent grant       1.00%  
University of Pittsburg License Agreement [Member]          
Research and Development Activity (Details) [Line Items]          
Percentage of net sales to pay royalties       2.50%  
United Kingdom [Member] | Research and Development Expense [Member]          
Research and Development Activity (Details) [Line Items]          
Research and development tax credit receivable       $ 3,319,000 $ 833,000
Reimbursements of research and development tax credit       814,000 306,000
Australia [Member]          
Research and Development Activity (Details) [Line Items]          
Reimbursements of research and development tax credit       1,296,000 178,000
Australia [Member] | Research and Development Expense [Member]          
Research and Development Activity (Details) [Line Items]          
Research and development tax credit receivable       $ 1,594,000 $ 853,000